• Je něco špatně v tomto záznamu ?

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

V. Grünwald, T. Powles, E. Kopyltsov, V. Kozlov, T. Alonso-Gordoa, M. Eto, T. Hutson, R. Motzer, E. Winquist, P. Maroto, B. Keam, G. Procopio, S. Wong, B. Melichar, F. Rolland, M. Oya, K. Rodriguez-Lopez, K. Saito, J. McKenzie, C. Porta

. 2023 ; 6 (4) : 437-446. [pub] 20230129

Jazyk angličtina Země Nizozemsko

Typ dokumentu randomizované kontrolované studie, multicentrická studie, časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016783

Grantová podpora
P30 CA008748 NCI NIH HHS - United States

BACKGROUND: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. OBJECTIVE: To perform an exploratory analysis of overall survival (OS) by tumor response by 6 mo, and to assess the efficacy and survival outcomes in specific subgroups. DESIGN, SETTING, AND PARTICIPANTS: CLEAR was an open-label, multicenter, randomized, phase 3 trial of first-line treatment of advanced clear cell RCC. INTERVENTION: Patients were randomized 1:1:1 to lenvatinib 20 mg orally daily with pembrolizumab 200 mg intravenously once every 3 wk, lenvatinib plus everolimus (not included in this analysis), or sunitinib 50 mg orally daily for 4 wk on treatment/2 wk of no treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Landmark analyses were conducted to assess the association of OS with tumor shrinkage and progressive disease status by 6 mo. Progression-free survival, duration of response, and objective response rate (ORR) were analyzed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup and by the presence of target kidney lesions. Efficacy was assessed by an independent review committee as per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS AND LIMITATIONS: Landmark analyses by tumor shrinkage showed that patients enrolled to lenvatinib plus pembrolizumab arm with a confirmed complete response or >75% target-lesion reduction by 6 mo had a 24-mo OS probability of ≥91.7%. A landmark analysis by disease progression showed that patients with no progression by 6 mo had lower probabilities of death in both arms. Patients with an IMDC risk classification of intermediate/poor had longer median progression-free survival (22.1 vs 5.9 mo) and a higher ORR (72.4% vs 28.8%) with lenvatinib plus pembrolizumab versus sunitinib. Similarly, results favored lenvatinib plus pembrolizumab in IMDC-favorable patients and those with/without target kidney lesions. Limitations of the study are that results were exploratory and not powered/stratified. CONCLUSIONS: Lenvatinib plus pembrolizumab showed improved efficacy versus sunitinib for patients with advanced RCC; landmark analyses showed that tumor response by 6 mo correlated with longer OS. PATIENT SUMMARY: In this report of the CLEAR trial, we explored the survival of patients with advanced renal cell carcinoma by assessing how well they initially responded to treatment. We also explored how certain groups of patients responded to treatment overall. Patients were assigned to cycles of either lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 wk or sunitinib 50 mg daily for 4 wk (followed by a 2-wk break). Patients who either had a "complete response" or had their tumors shrunk by >75% within 6 mo after starting treatment with lenvatinib plus pembrolizumab had better survival than those with less tumor reduction by 6 mo. Additionally, patients who had more severe disease (as per the International Metastatic Renal Cell Carcinoma Database Consortium) at the start of study treatment survived for longer without disease progression with lenvatinib plus pembrolizumab than with sunitinib.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016783
003      
CZ-PrNML
005      
20231026105541.0
007      
ta
008      
231013s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2023.01.010 $2 doi
035    __
$a (PubMed)36720658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Grünwald, Viktor $u Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany. Electronic address: Viktor.Gruenwald@uk-essen.de
245    10
$a Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study / $c V. Grünwald, T. Powles, E. Kopyltsov, V. Kozlov, T. Alonso-Gordoa, M. Eto, T. Hutson, R. Motzer, E. Winquist, P. Maroto, B. Keam, G. Procopio, S. Wong, B. Melichar, F. Rolland, M. Oya, K. Rodriguez-Lopez, K. Saito, J. McKenzie, C. Porta
520    9_
$a BACKGROUND: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. OBJECTIVE: To perform an exploratory analysis of overall survival (OS) by tumor response by 6 mo, and to assess the efficacy and survival outcomes in specific subgroups. DESIGN, SETTING, AND PARTICIPANTS: CLEAR was an open-label, multicenter, randomized, phase 3 trial of first-line treatment of advanced clear cell RCC. INTERVENTION: Patients were randomized 1:1:1 to lenvatinib 20 mg orally daily with pembrolizumab 200 mg intravenously once every 3 wk, lenvatinib plus everolimus (not included in this analysis), or sunitinib 50 mg orally daily for 4 wk on treatment/2 wk of no treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Landmark analyses were conducted to assess the association of OS with tumor shrinkage and progressive disease status by 6 mo. Progression-free survival, duration of response, and objective response rate (ORR) were analyzed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup and by the presence of target kidney lesions. Efficacy was assessed by an independent review committee as per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS AND LIMITATIONS: Landmark analyses by tumor shrinkage showed that patients enrolled to lenvatinib plus pembrolizumab arm with a confirmed complete response or >75% target-lesion reduction by 6 mo had a 24-mo OS probability of ≥91.7%. A landmark analysis by disease progression showed that patients with no progression by 6 mo had lower probabilities of death in both arms. Patients with an IMDC risk classification of intermediate/poor had longer median progression-free survival (22.1 vs 5.9 mo) and a higher ORR (72.4% vs 28.8%) with lenvatinib plus pembrolizumab versus sunitinib. Similarly, results favored lenvatinib plus pembrolizumab in IMDC-favorable patients and those with/without target kidney lesions. Limitations of the study are that results were exploratory and not powered/stratified. CONCLUSIONS: Lenvatinib plus pembrolizumab showed improved efficacy versus sunitinib for patients with advanced RCC; landmark analyses showed that tumor response by 6 mo correlated with longer OS. PATIENT SUMMARY: In this report of the CLEAR trial, we explored the survival of patients with advanced renal cell carcinoma by assessing how well they initially responded to treatment. We also explored how certain groups of patients responded to treatment overall. Patients were assigned to cycles of either lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 wk or sunitinib 50 mg daily for 4 wk (followed by a 2-wk break). Patients who either had a "complete response" or had their tumors shrunk by >75% within 6 mo after starting treatment with lenvatinib plus pembrolizumab had better survival than those with less tumor reduction by 6 mo. Additionally, patients who had more severe disease (as per the International Metastatic Renal Cell Carcinoma Database Consortium) at the start of study treatment survived for longer without disease progression with lenvatinib plus pembrolizumab than with sunitinib.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a sunitinib $x terapeutické užití $7 D000077210
650    12
$a nádory ledvin $x farmakoterapie $7 D007680
650    _2
$a progrese nemoci $7 D018450
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Powles, Thomas $u The Royal Free NHS Trust, London, England, UK
700    1_
$a Kopyltsov, Evgeny $u State Institution of Healthcare "Regional Clinical Oncology Dispensary", Omsk, Russia
700    1_
$a Kozlov, Vadim $u State Budgetary Health Care Institution "Novosibirsk Regional Clinical Oncology Dispensary", Novosibirsk, Russia
700    1_
$a Alonso-Gordoa, Teresa $u Hospital Universitario Ramón y Cajal, Madrid, Spain
700    1_
$a Eto, Masatoshi $u Kyushu University, Fukuoka, Japan
700    1_
$a Hutson, Thomas $u Texas Oncology, Dallas, TX, USA
700    1_
$a Motzer, Robert $u Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Winquist, Eric $u University of Western Ontario, London, Ontario, Canada
700    1_
$a Maroto, Pablo $u Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Keam, Bhumsuk $u Seoul National University Hospital, Seoul, Republic of Korea
700    1_
$a Procopio, Giuseppe $u Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
700    1_
$a Wong, Shirley $u Western Health, VIC, Australia
700    1_
$a Melichar, Bohuslav $u Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Rolland, Frederic $u Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France
700    1_
$a Oya, Mototsugu $u Keio University School of Medicine, Tokyo, Japan
700    1_
$a Rodriguez-Lopez, Karla $u Merck & Co., Inc, Rahway, NJ, USA
700    1_
$a Saito, Kenichi $u Eisai Inc, Nutley, NJ, USA
700    1_
$a McKenzie, Jodi $u Eisai Inc, Nutley, NJ, USA
700    1_
$a Porta, Camillo $u University of Bari 'A. Moro', Bari, Italy
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 6, č. 4 (2023), s. 437-446
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36720658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105535 $b ABA008
999    __
$a ok $b bmc $g 2000365 $s 1203145
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 6 $c 4 $d 437-446 $e 20230129 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace